Abstract 341P
Background
The three most famous NUP214-associated gene rearrangements found in leukemia patients are SET::NUP214, NUP214::ABL1, and DEK::NUP214. Regardless of the NUP214’s partner gene or disease type, one common feature NUP214 rearrangements have in common is their association with resistance to treatment and poor prognosis. However, numerous mouse model experiments have shown that NUP214 rearrangement alone is insufficient for, or at least inefficient at, leukemogenesis. Therefore, identification of concurrent mutations as well as sensitive detection of these fusion genes are important for accurate assessment and tailored management of leukemia patients.
Methods
To identify patients with NUP214 gene rearrangement, RNA sequencing results of diagnostic bone marrow aspirates were retrospectively reviewed. Concurrent targeted next generation sequencing results as well as the patients’ demographics, karyotype, and flow cytometry information were also reviewed.
Results
A total of ten patients harboring NUP214 gene rearrangement were identified, among which four had SET: NUP214, three had DEK: NUP214, and three had NUP214: ABL1. Their diagnosis varied depending on the fusion type. Concurrent gene mutations were found in all ten cases. PFH6 mutations was the most common (5/10) followed by WT1 (3/10), NOTCH1 (3/10), FLT3-ITD (3/10) NRAS (2/10), and EZH2 (2/10). One of these patients was the world’s second case of NUP214: ABL1-positive AML.
Conclusions
We have shown the patient characteristics and concurrent test results of ten NUP214-rearranged leukemia patients. Since these gene rearrangements can serve as potential minimal residual disease markers as well as therapeutic targets, we hope our elucidation of the context in which they were discovered will help future research in regard to tailored monitoring and treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract